Recursion Pharmaceuticals Inc (RXRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.99B
Last updated: Nov 17, 2026 at 4:44 PM ET
Recursion Pharmaceuticals Inc (RXRX) Stock Chart
Recursion Pharmaceuticals (RXRX) has a latest price of $2.72 on Nov 17, 2026. Its price fell 34.3% over the past 12 months. The month-end price fell 79.0% over the 5 years through Oct 2026, a compound annual decline of 26.8%.
Price Chart
From Apr 2021 to Oct 2026, its highest month-end close was $36.50 in Jun 2021 and its lowest $3.00 in Jul 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RXRX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RXRX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 22.3%, and over 6 months it fell 4.6%. The month-end price fell 23.7% over the 3 years through Oct 2026, a compound annual decline of 8.6%.
| Period | Change |
|---|---|
| 1 month | -24.7% |
| 3 months | -22.3% |
| 6 months | -4.6% |
| 12 months | -34.3% |
| 12 months, with dividends | -34.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -23.7% | -8.6% |
| 5 years | -79.0% | -26.8% |
Price by Year
Its best calendar year was 2023, when the price rose 27.9%, and its weakest was 2022, when it fell 55.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $4.03 | -1.5% |
| 2025 | $4.09 | -39.5% |
| 2024 | $6.76 | -31.4% |
| 2023 | $9.86 | +27.9% |
| 2022 | $7.71 | -55.0% |
Trading Range
The price is 27.5% below its 50-day average of $3.75 and 21.4% below its 200-day average of $3.46.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $2.72 | |
| 50-day average | $3.75 | -27.5% |
| 200-day average | $3.46 | -21.4% |
Price Risk
Over 3 years, its largest fall from a peak was 82.5%.
| Measure | Value |
|---|---|
| 1-year beta | 2.94 |
| Largest fall, 1 year | -45.2% |
| Largest fall, 3 years | -82.5% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RXRX
What is RXRX's 1-year price change?
Recursion Pharmaceuticals's price fell 34.3% over the past 12 months. With dividends included, the 12-month total return was -34.3%.
What is RXRX's 5-year price change?
Recursion Pharmaceuticals's month-end price fell 79.0% over the 5 years through Oct 2026, a compound annual decline of 26.8%. These figures leave out dividends.
What is RXRX's beta?
Recursion Pharmaceuticals's 1-year beta against the S&P 500 is 2.94, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 45.2%.
Is the RXRX chart free?
Yes. Advanced Charting for RXRX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RXRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors